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EDITORIAL  COMMENT
Introduction
Hepatitis C virus (HCV) affects approximately
170 million people worldwide. More than 80% of
patients with HCV infection progress into chronicity,
20–30% of patients with chronic hepatitis C progress
to cirrhosis after 10–20 years of follow-up, and some
develop hepatocellular carcinoma.1 Chronic HCV
infection is the most important cause of liver
transplantation in Western countries. Extrahepatic
manifestations in patients with chronic hepatitis C have
been clinically noticed. Among them, cryoglobinemia,
membranoproliferative glomerulonephritis, and
porphyria cutanea tarda are definitely associated with
HCV infection.2 For the remaining manifestations,
such as lichen planus, autoimmune thyroiditis, Sjögren’s
syndrome, and low-grade B-cell lymphoma, however,
the role of HCV is still under debate. Recently, the
association of chronic hepatitis C with diabetes mellitus
(DM) has gained much attention.
A large number of clues have suggested the potential
role of a common hepatotrophic virus in developing
diabetes. As many as 80% of patients with cirrhosis show
glucose intolerance, and 10–20% of them have DM.3
Physiologic glucose homeostasis is maintained by a
dynamic equilibrium between endogenous glucose
production and glucose use. These processes are
regulated mainly by insulin and glucagons. However,
liver also plays a crucial role in both endogenous glucose
production and glucose use.4 Glucose intolerance has
been demonstrated in cirrhotic patients because of insulin
resistance caused by a postreceptor defect, decreased
binding of insulin to target tissue, and inadequate
response of the beta cells of the pancreas to appropriately
secrete insulin to overcome the defect in insulin action.5
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Epidemiologic Studies of Serum HCV
Antibodies (Anti-HCV) in Patients With
Type 2 DM
Increased prevalence of positive serum anti-HCV has
been found in patients with DM.6,7 Simo et al7 showed
a significantly higher prevalence rate of positive serum
anti-HCV (11.5%) in 176 diabetic patients when
compared with 2.5% in 6,172 blood donors. In this
issue, Chen et al8 evaluated serum anti-HCV and
hepatitis B surface antigen (HBsAg) among 820 type
2 DM patients and 905 non-DM healthy check-up
subjects. They reported a higher seroprevalence of
HCV infection among patients with type 2 DM (6.8%)
than in the control group (2.6%) (odds ratio: 2.87;
95% confidence interval: 1.51–5.46), but no difference
in positive HBsAg between the groups (13.5% vs
12.4%). They found a 2.8 times higher risk of hepatitis
C in Chinese patients with type 2 DM.8 Chen et al’s
results are consistent with previous reports indicating
the possible association between type 2 DM and
chronic hepatitis C. However, the risk factors of
HCV infection should be evaluated in detail in this
kind of study. History of blood transfusion, tattooing,
intravenous drug abuse, hemodialysis, abortion,
nondisposable needle exposure, and frequent dental
procedures are all common routes for contracting
HCV infection in this area.9 High prevalence of
chronic hepatitis B in Taiwan is mainly due to perinatal
infection through an HBsAg-positive mother or
horizontal transmission at preschool age. Thus, the
similar HBsAg prevalence rate between type 2 DM
and controls could not exclude the risk of
nondisposable needle injection in contracting adult
HCV infection.
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Epidemiologic Studies of DM in
HCV-related Diseases
In 1994, Allison et al10 first reported the association of
chronic hepatitis C with DM, and gained extensive
attention thereafter. A number of studies have shown
that 13–33% (median 25%) of patients with chronic
HCV infection are diabetic.11–13 This prevalence is
significantly higher than that in matched healthy
controls. In 2000, Mehta et al14 reported an important
survey addressing a link between DM and HCV status
in a representative sample of the general population of
the USA through the Third National Health and
Nutrition Examination Survey (NHANES III). After
adjustment for DM confounding factors such as age,
race, high body mass index, and low socioeconomic
status, they found that persons older than 40 years of
age with HCV infection were 3 times more likely than
those without HCV to have type 2 DM (odds ratio:
3.77; 95% confidence interval: 1.8–7.87).
Additionally, a higher prevalence of DM has been
reported in HCV-infected patients compared with
those with other liver diseases such as chronic hepatitis
B, primary biliary cirrhosis, and primary sclerosing
cholangitis.11–13 The post-liver transplant setting also
provides a unique opportunity to address the
relationship between HCV and DM. The prevalence
of DM is higher in HCV-positive than in HCV-
negative liver transplant recipients.15 In addition,
de novo transient or persistent DM has occurred more
frequently in HCV-infected transplant recipients
than in HCV-negative subjects.16 Antonelli et al17 also
reported a large excess of type 2 DM (12.6%) among
noncirrhotic chronic hepatitis C patients over a sample
of the general population or age-matched noncirrhotic
chronic hepatitis B patients, indicating that the
associations between chronic HCV infection and DM
are independent of cirrhosis. All of these studies
disclosed a close relationship between HCV infection
and the development of DM.
Risk Factors of HCV Infection in the
Development of Type 2 DM/Impaired
Fasting Glucose
Despite the close relationship between HCV infection
and DM, the actual pathogenesis for HCV infection
to develop type 2 DM remains to be established.
Type 2 DM is a complex, multisystem disease with a
pathophysiology that includes a defect in insulin
secretion, increased hepatic glucose production, and
resistance to the action of insulin, all of which contribute
to the development of overt hyperglycemia. In addition,
obesity, aging, and genetic factors such as family
history of DM all may contribute to the development
of type 2 DM. All these factors make it difficult to
evaluate the pathogenic role of HCV infection in the
development of type 2 DM. In our previous study, an
age > 57 years, family history of DM, body mass index
> 25 kg/m2, and previous interferon treatment were
all independent factors for the development  of type 2
DM in patients with chronic hepatitis C.18  Interferon
has been shown to induce insulin resistance in the
splanchnic and peripheral tissues of patients with
HCV.19 Zein et al20 found  that, after excluding
chronic hepatitis C patients who received previous
interferon treatment, higher fibrotic stages in liver
histology and family history of DM were closely
associated with higher prevalence of DM and impaired
fasting glucose in patients with chronic hepatitis C.
Possible Pathogenesis of HCV Infection
in the Development of Type 2 DM
The pathogenic mechanisms causing DM in patients
with HCV infection are still not well understood,
although both insulin resistance and impaired insulin
secretion have been considered to play an important
role in the development of DM. In a transgenic mouse
model, the reduction of plasma glucose concentration
after intraperitoneal insulin injection was impaired in
HCV core-gene transgenic mice, displaying a higher
plasma glucose level than in control mice, as well as
significantly higher basal serum insulin levels, indicating
insulin resistance in HCV core-gene transgenic mice.21
Several studies have demonstrated insulin resistance
in patients with HCV-related chronic hepatitis, using
a homeostasis model assessment (HOMA).22 Narita
et al23 demonstrated that, using HOMA methods,
both insulin resistance and beta-cell dysfunction
contributed to glucose intolerance in chronic hepatitis
C patients. Delgado-Borrego et al24 reported that HCV
is independently associated with increased insulin
resistance among orthotopic liver transplant recipients.
Petit et al25 demonstrated that insulin resistance in
nondiabetic HCV-infected patients is correlated with
the staging of liver fibrosis and may occur early in the
course of HCV infection, even in nondiabetic patients.
More recently, the role of tumor necrosis factor
(TNF)-_ in the pathogenesis of DM in chronic hepatitis
C patients has gained extensive interest.26 TNF-_ has
been shown to inhibit insulin-stimulated tyrosine
phosphorylation of insulin receptor and insulin receptor
substrate 1 in adipocytes, stimulate lipolysis, and increase
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serum-free fatty acids, leading to insulin resistance in
muscle and liver, mediate hepatic insulin resistance to
increase hepatic glucose production, and down-regulate
genes in adipocytes encoding proteins such as insulin
receptor substrate 1, glucose transporter-4, peroxisome
proliferator-activated receptors, and adiponectin.
In addition, TNF-_ may reduce beta-cell function
by direct toxic effects, further contributing to the
development of DM. Recent studies have shown
significantly higher levels of soluble TNF-_ receptors in
diabetic HCV patients than in nondiabetic HCV patients
and controls.27 A link between chronic HCV infection,
TNF-_, and type 2 DM is an attractive hypothesis.
The HCV–diabetes association represents a major
public health problem. Between 2% and 5% of the
urban population in Taiwan are positive for serum
anti-HCV, and highly HCV-endemic villages were
noted in the west coast and central part of Taiwan.1
Many of them may have impaired glucose tolerance or
DM. Diabetes-related microvascular and macrovascular
complications are likely, and the ongoing hepatic
inflammatory response may contribute to atherogenesis.
Furthermore, both insulin resistance and diabetes can
adversely affect the course of chronic hepatitis C and
lead to enhanced steatosis, steatohepatitis, and liver
fibrosis,28 which may increase the risk of cirrhosis and
hepatocellular carcinoma. Further studies concerning
these issues are ongoing.
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